Mirtazapine Bluefish Pharmaceuticals (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases norepinephrine release, and by antagonizing 5‑HT2 and 5‑HT3 receptors. This dual action enhances overall serotonergic and noradrenergic neurotransmission, helping to alleviate depressive symptoms.

The appropriate dose of mirtazapine is determined by the prescribing clinician based on the individual’s clinical condition, response, and tolerability. Dosage may be adjusted over time, and patients should follow the prescriber’s instructions without self‑adjusting the amount.

Safety data for mirtazapine in pregnancy and lactation are limited. Clinicians should weigh potential benefits against possible risks and consider alternative therapies when appropriate. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss treatment options with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mirtazapine belongs to the NaSSA class, differing from selective serotonin reuptake inhibitors (SSRIs) and serotonin‑norepinephrine reuptake inhibitors (SNRIs). Its receptor profile often results in stronger sedative and appetite‑stimulating effects, which can be advantageous for patients with insomnia or weight loss, but may be less suitable for those concerned about these side effects.

Mirtazapine Bluefish Pharmaceuticals should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain its stability and potency.

Mirtazapine is taken orally, usually once daily in the evening due to its sedative properties. The tablet should be swallowed whole with water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious risks include agranulocytosis, severe neutropenia, seizures, hypersensitivity reactions, and the potential for increased suicidal thoughts, especially when therapy is initiated or dosage is changed. Patients should be monitored closely for any signs of these conditions.

Mirtazapine is contraindicated in patients who have taken monoamine oxidase inhibitors within the past 14 days, those with known hypersensitivity to the drug, and individuals with severe hepatic impairment. Caution is also advised for patients with uncontrolled cardiovascular disease or a history of seizures.